首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria.
【24h】

Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria.

机译:远程医疗可确保卒中中溶栓的安全和广泛使用:巴伐利亚州中风综合卒中远程医疗试验项目(TEMPiS)。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Systemic thrombolysis represents the only proven therapy for acute ischemic stroke, but safe treatment is reported only in established stroke units. One major goal of the ongoing Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria is to extend the use of tissue plasminogen activator (tPA) treatment in nonurban areas through telemedic support. METHODS: The stroke centers in Munich-Harlaching and in Regensburg established a telestroke network to provide consultations for 12 local hospitals in eastern Bavaria. The telemedic system consists of a digital network that includes a 2-way video conference system and CT/MRI image transfer with a high-speed data transmission up to 2 Mb/s. Each network hospital established specialized stroke wards in which qualified teams treat acute stroke patients. Physicians in these hospitals are able to contact the stroke centers 24 hours per day. RESULTS: A total of 106 systemic thrombolyses were indicated via teleconsultations between February 1, 2003, and April 7, 2004. During the first 12 months, the rate of thrombolyses was 2.1% of all stroke patients. Mean age was 68 years, and median National Institutes of Health Stroke Scale score was 13. Mean delay between onset and hospital admission was 65 minutes, and door-to-needle time was on average 76 minutes, which included 15 minutes for the teleconsultation. Symptomatic hemorrhage occurred in 8.5% of patients, and in-hospital mortality was 10.4%. CONCLUSIONS: The present data suggest that systemic thrombolysis indicated via stroke experts in the setting of teleconsultation exhibits similar complication rates to those reported in the National Institute of Neurological Disorders and Stroke trial. Therefore, tPA treatment is also safe in this context and can be extended to nonurban areas.
机译:背景与目的:全身溶栓是急性缺血性卒中的唯一有效疗法,但仅在既定的卒中单位中报告了安全的治疗方法。正在进行的巴伐利亚中风综合卒中远程医疗试验项目(TEMPiS)的一个主要目标是通过远程医疗支持在非城市地区扩展组织纤溶酶原激活剂(tPA)治疗的使用。方法:慕尼黑哈拉欣和雷根斯堡的中风中心建立了远程中风网络,为巴伐利亚东部的12家当地医院提供咨询。远程医疗系统由一个数字网络组成,该数字网络包括一个2路视频会议系统和CT / MRI图像传输,并具有高达2 Mb / s的高速数据传输。每个网络医院都建立了专门的中风病房,由合格的团队治疗急性中风患者。这些医院的医师可以每天24小时联系中风中心。结果:在2003年2月1日至2004年4月7日之间,通过远程咨询共发现了106例全身性血栓形成。在头12个月中,血栓形成率为所有中风患者的2.1%。平均年龄为68岁,美国国立卫生研究院卒中量表的中位数为13。发病至入院的平均延迟时间为65分钟,从门到针的平均时间为76分钟,其中包括15分钟的远​​程咨询。 8.5%的患者发生症状性出血,住院死亡率为10.4%。结论:目前的数据表明,在远程会诊中通过中风专家表明的全身溶栓显示出与美国国家神经病学和中风研究所的试验相似的并发症发生率。因此,在这种情况下,tPA治疗也是安全的,并且可以扩展到非城市地区。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号